Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Parrish

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
Blood Cancer Journal|April 2, 2022
Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial resultsHolger W Auner, Sarah R Brown, Katrina Walker, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 28, 2015
Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune ResponsesKarishma Rajani, Christopher Parrish, Timothy Kottke, et al.
Haematologica|January 29, 2026
Male sex adversely impacts survival and myeloid malignancy risk in MGUS: a real-world population-based studyEve Roman, Timothy Bagguley, Simon Crouch, et al.
British Journal of Cancer|April 10, 2026
Apoptotic modulators enhance oncolytic virus-induced cytokine killing in acute myeloid leukaemia (AML)Basem Askar, Samuel Heaton, Tyler Barr, et al.
Molecular Therapy Oncolytics|April 20, 2023
Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cellsMatthew Holmes, Gina B Scott, Samuel Heaton, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 30, 2014
Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory AgentsShane Zaidi, Miran Blanchard, Kevin Shim, et al.
British Journal of Haematology|September 4, 2025
Assessment and treatment of frail patientns living with multiple myeloma. A guideline on behalf of the UK Myeloma Research Alliance Frailty GroupSally Moore, Hannah Miller, Christopher Parrish, et al.
Frontiers in Oncology|August 9, 2021
Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple MyelomaCatherine S Y Lecat, Jessica B Taube, William Wilson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 2, 2016
Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) TrialChristopher Parrish, Curly T C M Morris, Cathy D Williams, et al.
Journal for Immunotherapy of Cancer|March 20, 2021
Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow nicheLouise M E Müller, Gemma Migneco, Gina B Scott, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
Blood Cancer Journal|April 2, 2022
Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial resultsHolger W Auner, Sarah R Brown, Katrina Walker, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 28, 2015
Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune ResponsesKarishma Rajani, Christopher Parrish, Timothy Kottke, et al.
Haematologica|January 29, 2026
Male sex adversely impacts survival and myeloid malignancy risk in MGUS: a real-world population-based studyEve Roman, Timothy Bagguley, Simon Crouch, et al.
British Journal of Cancer|April 10, 2026
Apoptotic modulators enhance oncolytic virus-induced cytokine killing in acute myeloid leukaemia (AML)Basem Askar, Samuel Heaton, Tyler Barr, et al.
Molecular Therapy Oncolytics|April 20, 2023
Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cellsMatthew Holmes, Gina B Scott, Samuel Heaton, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 30, 2014
Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory AgentsShane Zaidi, Miran Blanchard, Kevin Shim, et al.
British Journal of Haematology|September 4, 2025
Assessment and treatment of frail patientns living with multiple myeloma. A guideline on behalf of the UK Myeloma Research Alliance Frailty GroupSally Moore, Hannah Miller, Christopher Parrish, et al.
Frontiers in Oncology|August 9, 2021
Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple MyelomaCatherine S Y Lecat, Jessica B Taube, William Wilson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 2, 2016
Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) TrialChristopher Parrish, Curly T C M Morris, Cathy D Williams, et al.
Journal for Immunotherapy of Cancer|March 20, 2021
Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow nicheLouise M E Müller, Gemma Migneco, Gina B Scott, et al.
Pageof 6